Teva Research Development from 2010 to 2026
| TEVA Stock | USD 33.98 0.06 0.18% |
Research Development | First Reported 1998-03-31 | Previous Quarter 256 M | Current Value 267 M | Quarterly Volatility 195 M |
Check Teva Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Teva Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 724.7 M, Interest Expense of 961.8 M or Total Revenue of 10 B, as well as many indicators such as Price To Sales Ratio of 1.84, Dividend Yield of 0.0041 or PTB Ratio of 4.35. Teva financial statements analysis is a perfect complement when working with Teva Pharma Valuation or Volatility modules.
Teva | Research Development | Build AI portfolio with Teva Stock |
Analyzing Teva Pharma's Research Development over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Research Development has evolved provides context for assessing Teva Pharma's current valuation and future prospects.
Latest Teva Pharma's Research Development Growth Pattern
Below is the plot of the Research Development of Teva Pharma Industries over the last few years. It is Teva Pharma's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Teva Pharma's overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Teva Research Development Regression Statistics
| Arithmetic Mean | 1,218,709,686 | |
| Geometric Mean | 1,011,456,158 | |
| Coefficient Of Variation | 39.11 | |
| Mean Deviation | 355,062,612 | |
| Median | 1,095,000,000 | |
| Standard Deviation | 476,696,107 | |
| Sample Variance | 227239.2T | |
| Range | 2.1B | |
| R-Value | (0.09) | |
| Mean Square Error | 240368.4T | |
| R-Squared | 0.01 | |
| Significance | 0.73 | |
| Slope | (8,617,850) | |
| Total Sum of Squares | 3635826.8T |
Teva Research Development History
About Teva Pharma Financial Statements
Teva Pharma stakeholders use historical fundamental indicators, such as Teva Pharma's Research Development, to determine how well the company is positioned to perform in the future. Although Teva Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Teva Pharma's assets and liabilities are reflected in the revenues and expenses on Teva Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Teva Pharma Industries. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research Development | 1 B | 861.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out the analysis of Teva Pharma Correlation against competitors. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Teva Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.4 | Earnings Share 1.21 | Revenue Per Share | Quarterly Revenue Growth 0.114 | Return On Assets |
Understanding Teva Pharma Industries requires distinguishing between market price and book value, where the latter reflects Teva's accounting equity. The concept of intrinsic value - what Teva Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Teva Pharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Teva Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.